Fabry-Anderson disease: current state of knowledge

被引:0
作者
Vega-Vega, Olynka [1 ]
Perez-Gutierrez, Angelica [1 ]
Correa-Rotter, Ricardo [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Nefrol & Metab Mineral, Mexico City 14080, DF, Mexico
来源
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2011年 / 63卷 / 03期
关键词
Fabry-Anderson disease; Physiopathology; Lysosomal storage disease; alpha-galactosidase; Glycosphingolipids; ENZYME REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE-A; CLINICAL-MANIFESTATIONS; AGALSIDASE-BETA; ANTIBODY-FORMATION; PREVALENCE; STORAGE; DIAGNOSIS; DISORDER; CARRIER;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fabry-Anderson disease is a lysosomal storage disease caused by deficiency of the enzyme a-galactosidase. This enzymatic defect results in the accumulation of glycosphingolipid into different lines cells. Usually the deficiency is complete, resulting in a multisystem disorder, with injury in different organs, predominantly heart, kidney and nervous system. However, in some patients the enzymatic deficit is partial and causes diverse clinical variants of the disease (renal or cardiac variety), this cause a difficult diagnostic and the absence of real epidemiology data. This review is about the epidemiology, the metabolic defect of this disease, it's molecular and genetics bases, the different forms of clinical presentation and the enzyme replacement therapy.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 58 条
[1]   Renal pathology in Fabry disease [J].
Alroy, J ;
Sabnis, S ;
Kopp, JB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06) :S134-S138
[2]  
Anderson W., 1898, BRIT J DERMATOL, V10, P113, DOI 10.1111/j.1365-2133.1898.tb16317.x
[3]   Agalsidase-beta therapy for advanced Fabry disease - A randomized trial [J].
Banikazemi, Maryam ;
Bultas, Jan ;
Waldek, Stephen ;
Wilcox, William R. ;
Whitley, Chester B. ;
McDonald, Marie ;
Finkel, Richard ;
Packman, Seymour ;
Bichet, Daniel G. ;
Warnock, David G. ;
Desnick, Robert J. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (02) :77-86
[4]   Fabry disease in patients with end-stage renal failure: The potential benefits of screening [J].
Bekri, S ;
Enica, A ;
Ghafari, T ;
Plaza, G ;
Champenois, I ;
Choukroun, G ;
Unwin, R ;
Jaeger, P .
NEPHRON CLINICAL PRACTICE, 2005, 101 (01) :C33-C38
[5]   HUMAN ALPHA-GALACTOSIDASE-A - NUCLEOTIDE-SEQUENCE OF A CDNA CLONE ENCODING THE MATURE ENZYME [J].
BISHOP, DF ;
CALHOUN, DH ;
BERNSTEIN, HS ;
HANTZOPOULOS, P ;
QUINN, M ;
DESNICK, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (13) :4859-4863
[6]   ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY [J].
BRADY, RO ;
GAL, AE ;
BRADLEY, RM ;
MARTENSS.E ;
WARSHAW, AL ;
LASTER, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) :1163-&
[7]   Enzyme replacement for lysosomal diseases [J].
Brady, RO .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :283-296
[8]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[9]   Narrative review: Fabry disease [J].
Clarke, Joe T. R. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (06) :425-433
[10]  
COLOMBI A, 1967, HELV MED ACTA, V34, P67